Could a common diabetes drug protect PsA Patients' hearts?
NCT ID NCT05988684
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested whether adding metformin to standard care can slow the buildup of plaque in the carotid arteries of people with psoriatic arthritis (PsA) who do not have diabetes. Twenty-four participants with PsA and existing carotid plaque were randomly assigned to take metformin or not for one year. The goal was to see if metformin could reduce the risk of heart disease, a major cause of death in PsA patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Metformin (a diabetes drug)
- What this could lead to
- If it works, this could point toward a way to reduce heart disease risk in people with psoriatic arthritis.
- What could go wrong
- This is a very small pilot study with only 24 people, so results may not apply widely. Metformin can cause stomach upset, and the trial is open-label, which can bias results.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSA (PSORIATIC ARTHRITIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Chinese University of Hong Kong
Hong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.